- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01586494
A Pharmacokinetic, Tolerability, and Safety Study of ULTRAM ER in Children With Pain
August 28, 2012 updated by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
A Single Dose Pharmacokinetic, Tolerability, and Safety Study of ULTRAM ER at Two Dose Levels in Children Seven to Eleven Years Old, Inclusive, With Pain
The purpose of this study is to compare the pharmacokinetics (PK) of single oral doses of ULTRAM Extended Release (ER) at 2 dose levels in children between 7 and 11 years old, inclusive (up to 11 years 364 days) with pain due to injury or nonmalignant disease, to the PK in adults, with respect to the PK parameter AUC∞ (area under the curve) of racemic tramadol.
PK explores how the drug is absorbed in the body, distributed within the body, and how it is removed from the body over time.
Study Overview
Detailed Description
This is a multicenter, open-label (all people know the identity of the intervention), 2-group, single dose study.
Within each group of participants for Parts 1 and 2, at least 1/3 of the participants will be female, at least 1/3 of the participants will be male, at least 1/3 of the participants will be below the age of 8 years, and at least 1/3 of the participants will be above the age of 10 years.
Participants will be assigned to 1 group only.
Each group of participants will receive a single oral dose of ULTRAM ER on 1 occasion.
Group 1 will receive a dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.
Following completion of all evaluations of Group 1, the pharmacokinetic data will be evaluated to target a dose for Group 2 that will achieve a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
The maximum dose of ULTRAM ER should not exceed 6 mg/kg or 300 mg.
When the study physician, the investigators, and the medical monitors agree that the PK of the drug is well-characterized and that the drug is well tolerated, enrollment will begin for Group 2 of the study.
The sponsor's responsible Medical Officer will evaluate the safety of the calculated dose in Group 2 participants by evaluation of adverse drug events paying particular attention to events suggestive of either opioid toxicity or serotonin toxicity.
Study Type
Interventional
Enrollment (Actual)
37
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
7 years to 11 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Confirmed need for control of pain due to injury or nonmalignant disease that does not influence fluid shifts and general drug disposition
- Weighs at least 20 kg
- Female participants must be premenarchal and in the opinion of the investigator not sexually active
- Able to swallow the intact tablet with the aid of water (participants may not chew, divide, dissolve, or crush the study drug)
- Signed informed consent document indicating that he/she understands the purpose of and procedures required for the study and is willing to participate in the study
- Informed consent signed by the parent(s) or the legal guardian(s) of the participant
Exclusion Criteria:
- History of or current clinically significant medical illness or condition including (but not limited to) cardiac disease, hematologic disease, coagulation disorders, lipid abnormalities, significant pulmonary disease, diabetes mellitus, renal or hepatic insufficiency, thyroid disease, neurologic or psychiatric disease, infection, or any other illness or condition that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 2
|
One dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.
The target dose for Group 2 will be the one that achieves a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
|
Experimental: Group 1
|
One dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.
The target dose for Group 2 will be the one that achieves a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The area under the curve (AUC∞) of ULTRAM ER as the primary PK parameter
Time Frame: At 1, 4, 6, 8, 12, 16, 24, 36, and 48 hours post dose
|
At 1, 4, 6, 8, 12, 16, 24, 36, and 48 hours post dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Plasma concentration profile of ULTRAM ER
Time Frame: At 1, 4, 6, 8, 12, 16, 24, 36, and 48 hours post dose
|
At 1, 4, 6, 8, 12, 16, 24, 36, and 48 hours post dose
|
Plasma concentration profiles of M1 and M5 metabolites
Time Frame: At 1, 4, 6, 8, 12, 16, 24, 36, and 48 hours post dose
|
At 1, 4, 6, 8, 12, 16, 24, 36, and 48 hours post dose
|
Incidence of adverse events as a measure of safety and tolerability
Time Frame: 48 hours post dose
|
48 hours post dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Clinical Trial, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2007
Primary Completion (Actual)
June 1, 2009
Study Completion (Actual)
June 1, 2009
Study Registration Dates
First Submitted
April 25, 2012
First Submitted That Met QC Criteria
April 25, 2012
First Posted (Estimate)
April 26, 2012
Study Record Updates
Last Update Posted (Estimate)
August 29, 2012
Last Update Submitted That Met QC Criteria
August 28, 2012
Last Verified
August 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR014014
- TRAMAPPAI1002 (Other Identifier: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
Cairo UniversityCompletedCervical Pain | Lumbar Pain SyndromeEgypt
Clinical Trials on ULTRAM ER
-
Janssen Research & Development, LLCCompleted
-
University of IoanninaRecruitingScoliosis; AdolescenceGreece
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
INTRuST, Post-Traumatic Stress Disorder - Traumatic...U.S. Army Medical Research and Development CommandCompletedPost-Traumatic Stress DisorderUnited States
-
RVL Pharmaceuticals, Inc.Osmotica Pharmaceutical US LLCWithdrawnMultiple Sclerosis | SpermUnited States
-
Rhode Island HospitalCompletedOverweight and ObesityUnited States
-
Columbia UniversityBiolase IncActive, not recruitingPeri-ImplantitisUnited States
-
HealthPartners InstituteTerminated
-
TaiRx, Inc.CompletedAdvanced CancerTaiwan
-
Uppsala UniversityRecruitingADHD | Emotion Regulation | Attention Deficit Disorder With HyperactivitySweden